Adjust consistency: Add water gradually to achieve your desired consistency
This review provides a comprehensive overview of the diverse roles of ROS and their metabolic associations
For the complex structural model of FOXO4-DRI and p53 TAD2 we generated 1000 structural models of FOXO4-DRI bound to p53 TAD2
OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship
Using low-temperature micro-filtration and acid-free processing, we produce a non-denatured whey protein with naturally occurring immunoglobins, lactoferrin, and native growth factors, components that are lost when producing protein isolates and many other whey protein products